QQ客服 官方微博 反馈留言

浏览/检索结果: 共11条，第1-10条 帮助 限定条件 发表日期：2018     已选(0)清除 条数/页：5101520253035404550556065707580859095100   排序方式：请选择发表日期升序发表日期降序提交时间升序提交时间降序题名升序题名降序作者升序作者降序 Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients 会议论文 作者:  Chan, J.;  Hu, Z.;  Ili, D.;  Chuai, S.;  Shen, W. 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/05 Dynamic ctDNA Monitoring Revealed Novel Resistance Mechanisms and Response Predictors of Osimertinib Treatment in East Asian NSCLC Patients 会议论文 作者:  Chang, J.;  Hu, Z.;  Ji, D.;  Chuai, S.;  Shen, W. 收藏  |  浏览/下载：5/0  |  提交时间：2019/12/05 circulation tumor DNA  Acquired resistance  EGFR TKI   Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients. 期刊论文 Clinical Cancer Research, 2018, 卷号: 24, 期号: 13, 页码: 3097-3107 作者:  Yang, Zhe;  Yang, Nong;  Ou, Qiuxiang;  Xiang, Yi;  Jiang, Tao 收藏  |  浏览/下载：2/0  |  提交时间：2019/12/03 Targeting HER2 Aberrations in Non-Small Cell Lung Cancer with Osimertinib 期刊论文 CLINICAL CANCER RESEARCH, 2018, 卷号: 24, 期号: 11, 页码: 2594-2604 作者:  Liu, Shengwu;  Hai, Josephine;  Wang, Xiaoen;  Quinn, Max M.;  Gao, Peng 收藏  |  浏览/下载：81/0  |  提交时间：2019/04/28 Receptor Tyrosine Kinase  Phase-ii Trial  Bromodomain Inhibition  Combination Therapy  Acquired-resistance  Domain Mutations  Bet Bromodomains  Breast-cancer  Egfr  Mutant   BIM Deletion Polymorphism Confers Resistance to Osimertinib in EGFR T790M Lung Cancer: a Case Report and Literature Review 期刊论文 TARGETED ONCOLOGY, 2018, 卷号: 13, 期号: 4, 页码: 517-523 作者:  Li, Xuanzong;  Wang, Shijiang;  Li, Butuo;  Wang, Zhen;  Shang, Shuheng 收藏  |  浏览/下载：3/0  |  提交时间：2019/12/11 Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients 期刊论文 CLINICAL CANCER RESEARCH, 2018, 卷号: 24, 期号: 13, 页码: 3097-3107 作者:  Yang, Zhe;  Yang, Nong;  Ou, Qiuxiang;  Xiang, Yi;  Jiang, Tao 收藏  |  浏览/下载：6/0  |  提交时间：2019/12/11 Heterogeneity-based, multiple mechanisms in the resistance to osimertinib (AZD9291): A case report 期刊论文 2018, 卷号: 9, 期号: 4, 页码: 498-501 作者:  Liu, Yutao;  Hao, Xuezhi;  Hu, Xingsheng;  Li, Junling;  Wang, Yan 收藏  |  浏览/下载：6/0  |  提交时间：2020/01/03 Epidermal growth factor receptor T790 mutation  heterogeneity  MET amplification  osimertinib  resistance   Investigating Novel Resistance Mechanisms to Third-Generation EGFR Tyrosine Kinase Inhibitor Osimertinib in Non-Small Cell Lung Cancer Patients 期刊论文 2018, 卷号: 24, 期号: 13, 页码: 3097-3107 作者:  Yang, Zhe;  Yang, Nong;  Ou, Qiuxiang;  Xiang, Yi;  Jiang, Tao 收藏  |  浏览/下载：4/0  |  提交时间：2020/01/03 Acquired &ITEGFR&IT L718V mutation mediates resistance to osimertinib in non-small cell lung cancer but retains sensitivity to afatinib 期刊论文 2018, 卷号: 118, 页码: 1-5 作者:  Liu, Yutao;  Li, Yan;  Ou, Qiuxiang;  Wu, Xue;  Wang, Xiaonan 收藏  |  浏览/下载：2/0  |  提交时间：2020/01/03 EGFR  L718V  Osimertinib  Afatinib  Resistance  NSCLC   Resistance Mechanisms of Osimertinib in Chinese Non-Small Cell Lung Cancer patients: Analysis from AURA17 Trial 期刊论文 2018, 卷号: 13, 期号: 10, 页码: S345-S345 作者:  Zhou, C.;  Hu, M.;  Zhu, X.;  Sun, Y.;  Lu, X. 收藏  |  浏览/下载：1/0  |  提交时间：2020/01/03 non-small cell lung cancer  osimertinib  resistance mechanisms